Amendments to the Specification:

Please amend the paragraph beginning at page 3, line 16, as follows:

The invention provides a percutaneously absorbable preparation containing an acidic drug having salt-form and an addition salt compound of a basic substance in a basis.

Please amend the paragraph beginning at page 4, line 3, as follows:

The acidic drug having salt-form of the invention is not specifically limited so long as it is acceptable as medicines. The salts of salt-form in acidic drugs are metals such as alkali metals, alkali earth metals, aluminum and the like, amines such as tromethamine, and the like. Specific drugs include, for example, hypnotic sedative/anti-anxiety medicines (sodium amobarbital, sodium secobarbital, sodium phenobarbital, triclofos sodium dipotassium clorazepate and the like), anti-inflammatory medicines (sodium salicylate, sulpyrine, sodium amfenac, sodium dichlorofenac, sodium loxoprofen, sodium tolmetin, disodium lobenzarit, ketorolac tromethamine, sodium ketoprofen, sodium ibuprofen, sodium felbinac, sodium flurbiprofen, sodium indomethacin, sodium zomerac, flufenamic acid aluminum, calcium fenoprofen, sodium bromofenac, sodium hydrocortisone succinate, sodium hydrocortisone phosphate, sodium dexamethasone phosphate, sodium decamethasone metasulfobenzoate, sodium betamethasone phosphate, sodium prednisolone succinate, sodium prednisolone phosphate, sodium methyl prednisolone succinate, sodium prasterone sulfate and the like), muscular relaxant medicines (sodium dantrolene, sodium mivacurium and the like), cardiotonic medicines, (sodium bucladesine and the like), diuretic medicines (sodium theobromine, potassium perrhenate, and the like), cardiovascular medicines (sodium ozagrel, sodium pravastatin, calcium nisvastatin and the like), medicines for allergy (sodium cromoglycate, potassium perirolaste and the like), medicines for skin diseases (ciclopirox olamine and the like),

blood coagulation inhibitors (potassium warfarin and the like), and medicines for diabetes mellitus (sodium glymidine and the like). ,

Please amend the paragraph beginning at page 10, line 3, as follows:

Surfactant may be either ionic or non-ionic surfactants, but non-ionic surfactants is preferable in terms of skin safety. Examples of such surfactants include sorbitan fatty acid ester (e.g., sorbitan monostearate, sorbitan monoisostearate, sorbitan sesquioleate and the like), glycerine fatty acid ester (e.g., glyceryl monostearate, glyceryl monomyristate and the like), polyglycerine fatty acid ester (e.g., diglyceryl monooleate, diglyceryl monisostearate, decaglyceryl pentastearate, tetraglyceryl monostearate and the like), polyethylene glycol fatty acid ester (e.g., polyoxyethlene glycol (2) monostearate, polyoxyethylene glycol(2) monooleate and the like), polyoxyethylene alkyl phenyl ether (e.g., polyoxyethlene(2) nonyl phenyl ether, polyoxyethlene(5) nonyl phenyl ether and the like). Among them polyoxyethylene(2) ~~polyoxyethylene(5)~~ nonyl phenyl ether of which HLB is 10 or less, decaglyceryl pentastearate, diglyceryl monooleate, diglyceryl monoisostearate, and sorbitan monoisostearate are especially preferable. The quantity to be combined is from 1 to 10% by weight and preferably from 1 to 5% by weight based on the entire quantity of the ointment. When the quantity to be combined is less than 1% by weight, stability for a long time is impaired. When it is 10% or more by weight, it is not preferable because surface tackiness is remarkably increased.

Please amend the paragraph beginning at page 34, line 10, as follows:

The ~~patch~~ ointment was manufactured by way of trial by the same composition and process for production as those in Example 19, except that ammonium chloride which is the addition salt compound of the basic substance was not combined.

Please amend the paragraph beginning at page 34, line 14, as follows:

The ointment ~~patch~~ was manufactured by way of trial by the same composition and process for production as those in Example 20, except that ammonium chloride which is the addition salt compound of the basic substance was not combined.

Please amend the paragraph beginning at page 10, line 3, as follows:

The ointment ~~patch~~ was manufactured by way of trial by the same composition and process for production as those in Example 21, except that n-dodecyl trimethyl ammonium chloride which is the addition salt compound of the basic substance was not combined.